arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

MBX Biosciences, Inc.

MBX

$67.82 ▲ +0.84 (+1.26%) at close

14 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

MBX Biosciences, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $3.2B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -4.9% ↗

FCF / Share $-0.44

Trailing P/E —

Price / Book 7.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-23.52M

↑ +1.5% —

FCF / Share Free cash flow per share

$-0.44

↑ +34.8% —

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	29.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	77.3% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	95.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	93.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	70.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	1.5% Caution ↑ Caution Improving Year-over-year change in net income	-41.6% Weak ↑ Weak Improving Year-over-year change in net income	-93.6% Weak ↓ Weak Declining Year-over-year change in net income	-93.6% Weak → Weak Stable Year-over-year change in net income	-93.6% Weak → Weak Stable Year-over-year change in net income	-76.3% Weak Weak Year-over-year change in net income	-107.4% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	34.8% Excellent Excellent Year-over-year change in free cash flow	—	—	95.0% Excellent Excellent Year-over-year change in free cash flow	92.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	—	1.11x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.27x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-4.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-4.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	13.4% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	12.7% Good → Good Stable Return earned on debt + equity capital invested Optimal: > 10%	10.9% Good Good Return earned on debt + equity capital invested Optimal: > 10%	13.3% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-6.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-6.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-11.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-5.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-136%)	-6.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-140%)	-6.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-141%)	-10.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-173%)	-10.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-168%)	-6.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-140%)	-4.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-130%)	12.6% Fair → Fair Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-16%)	14.9% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	12.2% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-19%)	9.2% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-39%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-45.21M	$-75.29M	$-223.12M	$-39.78M	$-29.90M	$-49.35M	$-132.87M	—	—	$-30.52M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.50	$-0.45	$-0.63	$-0.58	$-0.71	$9.60	$-2.78	$-12.62	$-10.26	$-7.68	$-9.40	—	—	—
Free Cash Flow per Share (USD)	$-0.44	—	$-0.64	$-0.54	$-0.68	—	—	$-10.92	$-9.13	—	—	—	—	—
Book Value per Share (USD)	$9.20	$8.22	$8.67	$6.53	$7.04	$7.70	$8.13	$-77.90	$-69.07	$-57.65	$-59.94	—	—	—
Tangible Book Value per Share (USD)	$9.20	$8.22	$8.67	$6.53	$7.04	$7.70	$8.13	$-77.90	$-69.07	$-57.65	$-59.94	—	—	—
Basic Weighted Avg Shares (shares)	46.58M	—	34.20M	33.45M	33.41M	—	6.52M	1.26M	1.20M	—	1.08M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$433.97M	$366.04M	$385.44M	$217.43M	$233.79M	$256.24M	$270.25M	—	—	$79.54M	—	—	—	—
Total Equity (USD)	$437.76M	$369.22M	$387.54M	$219.24M	$235.42M	$257.44M	$271.37M	$-97.89M	$-83.05M	$-72.47M	$-64.82M	$-55.39M	$-48.27M	$-42.60M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$64.00K	$60.00K	$100.00K	$100.00K	$77.00K	$58.00K	$100.00K	$100.00K	$48.00K	$41.00K	$100.00K	—	—	—
Net Income, GAAP (USD)	$-23.52M	$-22.06M	$-23.88M	$-23.88M	$-23.88M	$-15.59M	$-12.34M	$-12.34M	$-12.34M	$-8.84M	$-5.95M	—	—	—
Operating Cash Flow (USD)	$-20.21M	$-18.30M	$-21.54M	$-17.43M	$-22.68M	$-16.04M	—	$-13.27M	$-10.71M	$-11.15M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

MBX Biosciences, Inc.

Analytical Summary

14-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare MBX with peers